The PI involved in the project Dr. Bart Roucourt, he holds a PhD in Bio-science engineering. As Head of Contract Research, he is responsible for the management of preclinical in vivo efficacy studies in transgenic mouse models of Alzheimer’s disease. Before starting as Contract Research Manager, he was Quality & HSE Manager at reMYND. Prior to this, Bart was postdoctoral researcher at KU Leuven’s Center for Human Genetics, managed a Biacore facility and obtained a PhD in Bioscience engineering at KU Leuven.
reMYND NV, founded in 2002 as a spin-off from the University of Leuven,
drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes
and other orphan protein misfolding disorders. reMYND is organized
along two independently managed business units, the Contract Research
Organization (CRO) and the own Drug Discovery & Development unit:
2.We discover and develop our own proprietary disease-modifying treatments against protein-misfolding disorders, such as Diabetes, Alzheimer's disease, Parkinson's disease, Huntington and amyotrophic lateral sclerosis, treating the root causes rather than only the symptoms. We are exploring collaborations on those programs with large pharma companies worldwide.
This project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 686009